Trial Profile
A Phase IIIb, Open-label, Multi-center 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of Ranibizumab (0.3 mg and/or 0.5 mg) in Patients With Subfoveal Choroidal Neovascularizstion Secondary to Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Adverse reactions; Registrational
- Acronyms SUSTAIN
- Sponsors Novartis
- 15 Aug 2014 New trial record
- 30 Oct 2008
- 04 Oct 2007